All In Biotech

Drug Trial Radar · NCT07000357

A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event

A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients With Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event

Last checked: Nov 19, 2026Latest source record: Aug 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 15,100 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

15,100

Planned (sponsor's estimate)

Start

Jun 4, 2025

Primary completion

Oct 26, 2029

Study completion Oct 26, 2029

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jun 2, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this phase 3, randomized, placebo controlled, event-driven study is to assess the effect of AZD0780, an oral PCSK9 inhibitor, compared with placebo in reducing the risk of MACE-PLUS in patients with established ASCVD or at high risk for a first ASCVD event. The effect of AZD0780 vs placebo on the risk of MACE-PLUS will be evaluated from randomisation until the primary analysis censoring date (PACD). The Study Closure Visit will be scheduled to occur after the PACD and will be the final visit for each participant in the study.

Conditions

  • Cardiovascular Disease

Interventions

  • AZD0780Drug

    Participants will receive oral AZD0780 once daily

  • PlaceboDrug

    Participants will receive oral placebo once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to first event of any component of MACE-PLUSTime frame: Up to approximately 54 months

Locations

1,452 sites in 36 countries. Site status is shown where the registry gives one.

  • Research Site

    Athens, Alabama · Recruiting

  • Research Site

    Birmingham, Alabama · Recruiting

  • Research Site

    Birmingham, Alabama · Not yet recruiting

  • Research Site

    Fairhope, Alabama · Recruiting

  • Research Site

    Foley, Alabama · Recruiting

  • Research Site

    Huntsville, Alabama · Withdrawn

  • Research Site

    Huntsville, Alabama · Not yet recruiting

  • Research Site

    Irondale, Alabama · Not yet recruiting

  • Research Site

    Mobile, Alabama · Recruiting

  • Research Site

    Northport, Alabama · Not yet recruiting

  • Research Site

    Saraland, Alabama · Recruiting

  • Research Site

    Vestavia Hills, Alabama · Recruiting

  • Research Site

    Gilbert, Arizona · Not yet recruiting

  • Research Site

    Gilbert, Arizona · Recruiting

  • Research Site

    Glendale, Arizona · Terminated

  • Research Site

    Mesa, Arizona · Withdrawn

  • Research Site

    Peoria, Arizona · Recruiting

  • Research Site

    Phoenix, Arizona · Not yet recruiting

  • Research Site

    Phoenix, Arizona · Recruiting

  • Research Site

    Phoenix, Arizona · Recruiting

  • Research Site

    Phoenix, Arizona · Recruiting

  • Research Site

    Scottsdale, Arizona · Recruiting

  • Research Site

    Tempe, Arizona · Recruiting

  • Research Site

    Tucson, Arizona · Recruiting

  • Research Site

    Tucson, Arizona · Withdrawn

  • Research Site

    Tucson, Arizona · Recruiting

  • Research Site

    Little Rock, Arkansas · Recruiting

  • Research Site

    Beverly Hills, California · Recruiting

  • Research Site

    Canoga Park, California · Recruiting

  • Research Site

    Castroville, California · Recruiting

  • Research Site

    Chula Vista, California · Recruiting

  • Research Site

    Fountain Valley, California · Recruiting

  • Research Site

    Garden Grove, California · Recruiting

  • Research Site

    La Jolla, California · Not yet recruiting

  • Research Site

    Lake Forest, California · Withdrawn

  • Research Site

    Lancaster, California · Recruiting

  • Research Site

    Loma Linda, California · Recruiting

  • Research Site

    Loma Linda, California · Recruiting

  • Research Site

    Los Angeles, California · Recruiting

  • Research Site

    Los Angeles, California · Recruiting

Showing 40 of 1,452 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.